Michael Lee Milligan

CIK: 0001993953

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (8.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)12 (52.2%)

Compensation grants

Other (G, F, J, C, D, …)9 (39.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NMRA

Neumora Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (23 total)

NMRA
Neumora Therapeutics, Inc.
Aug 20, 2026
Award(A)
Stock Option (Right to Buy)
Direct
175K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 17, 2026
Sale(S)
Direct
1.4K shares at avg. $3.56$5K
NMRA
Neumora Therapeutics, Inc.
Jan 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
350K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
38.2K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
41.3K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
85.4K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
38.2K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.7K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
41.3K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.7K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
85.4K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 18, 2025
Sale(S)
Direct
2K shares at avg. $1.69$3K
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
38.2K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.7K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
41.3K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
85.4K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
38.2K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.7K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
41.3K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
85.4K shares-

		Type	Shares	Price		Ownership
Aug 20, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	175,000	-	-	Direct
Feb 17, 2026	NMRA Neumora Therapeutics, Inc.	Sale(S)	1,436	$3.56	$5,119	Direct
Jan 8, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	350,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	38,234	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	41,250	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	400,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	85,391	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	38,234	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,675	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	41,250	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	400,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,675	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	85,391	-	-	Direct
Feb 18, 2025	NMRA Neumora Therapeutics, Inc.	Sale(S)	1,978	$1.69	$3,351	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	400,000	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	38,234	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,675	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	41,250	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	85,391	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	38,234	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,675	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	41,250	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	85,391	-	-	Direct

1-23 of 23 transactions

About Milligan Michael Lee

Milligan Michael Lee (SEC CIK 0001993953) files insider reports with the SEC as Officer of Neumora Therapeutics, Inc. (NMRA).

Signal8 holds 6 ownership filings by Milligan Michael Lee, all Form 4s, filed between Feb 18, 2025 and Aug 21, 2026. Those filings report 23 transactions, from Feb 13, 2025 to Aug 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Milligan Michael Lee's filings is in WATERTOWN, MA.

Recent filings by Milligan Michael Lee

Aug 20, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
Feb 17, 2026: Open-market sale of NMRA shares (Form 4, code S).
Jan 8, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
May 28, 2025: Disposition to issuer transactions of NMRA derivative securities (3 lines, Form 4, code D).
May 28, 2025: Grants or awards of NMRA derivative securities (5 lines, Form 4, code A).

Other insiders filing for Neumora Therapeutics, Inc. (NMRA)

How to read Form 4 transaction codes